Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.

[1]  A. Bezjak,et al.  Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. , 2007, The Journal of thoracic and cardiovascular surgery.

[2]  H. Hammad,et al.  Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses , 2006, European Respiratory Journal.

[3]  P. Jänne,et al.  Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[5]  yang-xin fu,et al.  Tumor-infiltrating T lymphocytes: friends or foes? , 2006, Laboratory Investigation.

[6]  R. Flores.  Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. , 2005, Lung cancer.

[7]  W. Hong,et al.  Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[9]  C. June,et al.  Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma , 2005, Cancer biology & therapy.

[10]  B. Robinson,et al.  Malignant mesothelioma. , 2005, Lancet.

[11]  R. Stahel,et al.  Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[13]  N. Ordóñez,et al.  Application of Mesothelin Immunostaining in Tumor Diagnosis , 2003, The American journal of surgical pathology.

[14]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Larson,et al.  Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. , 2003, The Journal of thoracic and cardiovascular surgery.

[16]  J. Frelinger,et al.  Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1 , 2003, The Journal of Immunology.

[17]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[18]  Timothy Zhu,et al.  A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. , 2003, The Annals of thoracic surgery.

[19]  M. Paesmans,et al.  Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. , 2002, Lung cancer.

[20]  J. Breau,et al.  Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study. , 2002, Chest.

[21]  P. Bruzzi,et al.  Combined regimen of cisplatin, doxorubicin, and α‐2b interferon in the treatment of advanced malignant pleural mesothelioma , 2001 .

[22]  A. Ardizzoni,et al.  Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. , 2001, Lung cancer.

[23]  P. Bruzzi,et al.  Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). , 2001, Cancer.

[24]  W. Richards,et al.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. , 1999, The Journal of thoracic and cardiovascular surgery.

[25]  P. Astoul,et al.  Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma , 1998, Cancer.

[26]  P. Terrier,et al.  Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  V. Rusch.  A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. , 1995, Chest.

[28]  I. Webster,et al.  Lymphocytic infiltration of pleural mesothelioma and its significance for survival. , 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.